Emergo Therapeutics
Emergo Therapeutics is dedicated to developing groundbreaking treatments that restore immune system balance, focusing on conditions like cytokine storm, Long COVID, and influenza-like illnesses. Founded in 2016, the company aims to revolutionize treatment approaches by targeting immune response modulation without causing immunosuppression.
Industries
biopharma
biotechnology
clinical-trials
pharmaceutical
Nr. of Employees
small (1-50)
Emergo Therapeutics
Durham, North Carolina, United States, North America
Products
Clinical-stage mast cell cytokine-release inhibitor (lead therapeutic program)
A clinical-stage host-targeted therapeutic that reduces overproduction and secretion of inflammatory cytokines from mast cells and related immune components, designed to treat acute influenza-like illnesses and chronic post-viral syndromes without inducing immunosuppression.
Clinical-stage mast cell cytokine-release inhibitor (lead therapeutic program)
A clinical-stage host-targeted therapeutic that reduces overproduction and secretion of inflammatory cytokines from mast cells and related immune components, designed to treat acute influenza-like illnesses and chronic post-viral syndromes without inducing immunosuppression.
Expertise Areas
- Immune modulation therapies
- Host-targeted therapeutics for respiratory and post-viral illnesses
- Clinical development for infectious and post-viral indications (Phase 1 through dose-optimization)
- Preclinical safety and toxicology
Key Technologies
- Host-targeted immunomodulatory therapeutics
- Mast cell–targeted cytokine-release inhibition
- Small-molecule clinical-stage therapeutic development
- Preclinical toxicology and GLP study management